Autologous peripheral blood T lymphocytes transduced with an anti lewisy chimeric receptor gene can be infused safely and persist in patients with lewisy positive acute myeloid leukaemia

      High-risk acute myeloid leukaemia (AML) has a dismal prognosis with available treatments. This phase 1 study evaluated safety and immunological effects of infusing peripheral blood T-lymphocytes transduced with an anti-LewisY (LeY) chimeric antigen (CAR) receptor gene in high-risk patients with LeY positive AML.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect